| Cross-sectional study | Longitudinal study |
---|---|---|
Number of patients | 84 | 56 |
Sex: male | 76 (90%) | 51(91%) |
Age (median, range) | 43 (24 - 70) | 41 (24 - 62) |
Rise factor | Â | Â |
Haemophilia | 56 (67%) | 35 (63%) |
i. v. drugs | 22 (26%) | 16(29%) |
man who have sex with man | 6 (7%) | 5 (9%) |
HCV-RNA negative | 14(17%) | 5 (9%) |
HCV viral load > 800000 1 U/1 | 55 (66%) | 39 (70%) |
HCV-Genotype | Â | Â |
1 | 52 (62%) | 39 (72%) |
2 | 6(7%) | 3 (6%) |
3 | 13(16%) | 10(19%) |
4 | 4 (5%) | 2 (4%) |
HAART | 67 (82%) | 46 (84%) |
PI-based HAART | 50 (75%) | 37 (80%) |
NNRTI-based HAART | 17 (25%) | 9 (20%) |
< 50 HIV copies/ml | 62 (74%) | 43 (77%) |
CD4-Count (median, range) [cell/μl | 397 (10 - 1757) | 394 (10 - 966) |
AST (median, range) [U/l] | 47 (21 - 197) | 48 (21 - 197) |
ALT (median, range) [U/l] | 72 (8 - 275) | 77 (16 - 275) |
Platelets (median, range) [T/l] | 160 (9 - 337) | 148 (9 - 325) |
Stiffness (median, range) [kPa] | 7.4 (3.3 - 48) | 7.8 (3.3 - 48) |
APRI (median, range) | n = 75 | n = 52 |
 | 0.9 (0.3 - 43.2) | 11.1 (0.4 - 43.2) |
FIB-4 (median, range) | n = 75 | n = 52 |
 | 11.6 (0.5 - 50.3) | 11.6 (0.5 - 50.3) |
IL28B genotype: | Â | Â |
CC | 42 (50%) | 26 (46%) |
CT | 36 (43%) | 25 (45%) |
TT | 6(7%) | 5 (9%) |
Time of follow-up (median, range) [months] | 25 (5 - 50) |